Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185]

The objective was to study the effect of whole-body vibration (WBV) on strength, balance and pain in patients with peripheral neuropathies and to consider its significance for the rehabilitation of patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). Using a broad search strategy, PubMed was searched for clinical trials on WBV interventions aimed at improving strength, balance or pain in patients with peripheral neuropathies, which were published in English until 5th June 2014. The search was performed by the first author and generated a total of 505 results, which yielded 5 articles that met the inclusion criteria, being studies: i) published in English; ii) involving adult human subjects’ peripheral neuropathies; iii) evaluating the effect of WBV as a therapeutic intervention; and iv) reporting findings for at least one of the following outcomes: strength, balance or pain. Methodological quality of included studies was assessed independently by first and second author, using the physiotherapy evidence database scale. The overall methodological quality of included studies was low. Two studies found a beneficial effect of WBV on neuropathic pain, but another study failed to find the same effect. One study found significant improvements in both muscle strength and balance, while another study found improvements only in some, but not all, of the applied tests to measure muscle strength and balance. The results of this literature search suggest insufficient evidence to assess the effectiveness for the effects of WBV on neuropathic pain, muscle strength and balance in patients with peripheral neuropathies. More high-quality trials are needed to guide the optimization of rehabilitation programs for cancer survivors with CIPN in particular.

Download Full-text

Peripheral Neuropathy: Comparison of Symptoms and Severity Between Colorectal Cancer Survivors and Patients With Diabetes

Clinical Journal of Oncology Nursing ◽

10.1188/21.cjon.395-403 ◽

2021 ◽

Vol 25 (4) ◽

pp. 395-403

Author(s):

Chih-Jung Wu ◽

Kuan-Jung Huang ◽

Yi-Chuan Tsai ◽

Tzu-Pei Yeh ◽

Chia-Fen Hsieh ◽

...

Keyword(s):

Colorectal Cancer ◽

Peripheral Neuropathy ◽

Cancer Survivors ◽

Colorectal Cancer Survivors ◽

Patients With Diabetes

Download Full-text

(215) Differential Expression of Axonal Transport Related Genes and Pathways in Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Survivors

Journal of Pain ◽

10.1016/j.jpain.2019.01.136 ◽

2019 ◽

Vol 20 (4) ◽

pp. S29

Author(s):

K. Kober ◽

J. Levine ◽

J. Mastick ◽

B. Cooper ◽

C. Paul ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Survivors ◽

Differential Expression ◽

Axonal Transport ◽

Breast Cancer Survivors

Download Full-text

Development and validation of the comprehensive assessment scale for chemotherapy–induced peripheral neuropathy in survivors of cancer

BMC Cancer ◽

10.1186/s12885-019-6113-3 ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

K. Kanda ◽

K. Fujimoto ◽

R. Mochizuki ◽

K. Ishida ◽

B. Lee

Keyword(s):

Factor Analysis ◽

Peripheral Neuropathy ◽

Cancer Survivors ◽

Cancer Patients ◽

Internal Consistency ◽

Reliability And Validity ◽

Comprehensive Assessment ◽

Assessment Scale ◽

Fine Motor ◽

Gynecologic Oncology Group

Abstract Background Appropriate assessment is essential for the management of chemotherapy-induced peripheral neuropathy (CIPN), an intractable symptom that cannot yet be palliated, which is high on the list of causes of distress for cancer patients. However, objective assessment by medical staff makes it easy to underestimate the symptoms and effects of CIPN in cancer survivors. As a result, divergence from subjective evaluation of cancer survivors is a significant problem. Therefore, there is an urgent need to develop a subjective scale with high accuracy and applicability that reflects the experiences of cancer patients. We developed a comprehensive assessment scale for CIPN in cancer survivors, named the Comprehensive Assessment Scale for Chemotherapy-Induced Peripheral Neuropathy in Survivors of Cancer (CAS-CIPN), and demonstrated its reliability and validity. Methods We developed a questionnaire based on qualitative studies of peripheral neuropathy in Japanese cancer patients and literature review. Twelve cancer experts confirmed the content validity of the questionnaire. A draft version comprising 40 items was finalized by a pilot test on 100 subjects. The participants in the present study were 327 Japanese cancer survivors. Construct validity was determined by factor analysis, and internal validity by confirmation factor analysis and Cronbach’s α. Results Factor analysis showed that the structure consisted of 15 items in four dimensions: “Threatened interference in daily life by negative feelings”, “Impaired hand fine motor skills”, “Confidence in choice of treatment/management,” and “Dysesthesia of the palms and soles.” The CAS-CIPN internal consistency reliability was 0.826, and the reliability coefficient calculated using the Spearman-Brown formula [q = 2r/(1 + r)] was 0.713, confirming high internal consistency and stability. Scores on this scale were strongly correlated with Gynecologic Oncology Group-Neurotoxicity scores (r = 0.714, p < 0.01), confirming its criterion-related validity. Conclusions The CAS-CIPN is an assessment tool with high reliability and validity for the comprehensive evaluation of CIPN in cancer survivors. The CAS-CIPN is simple to use, and can be used by medical professionals for appropriate situational assessment and intervention.

Download Full-text

Acupuncture for Chemotherapy‐Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial

The Oncologist ◽

10.1634/theoncologist.2019-0489 ◽

2019 ◽

Vol 25 (4) ◽

pp. 310-318 ◽

Cited By ~ 12

Author(s):

Weidong Lu ◽

Anita Giobbie‐Hurder ◽

Rachel A. Freedman ◽

Im Hee Shin ◽

Nancy U. Lin ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Pilot Trial ◽

Randomized Controlled

Download Full-text

Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain

Molecular Pain ◽

10.1177/1744806920936502 ◽

2020 ◽

Vol 16 ◽

pp. 174480692093650 ◽

Cited By ~ 2

Author(s):

Kord M Kober ◽

Man-Cheung Lee ◽

Adam Olshen ◽

Yvette P Conley ◽

Marina Sirota ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Sciatic Nerve ◽

Cancer Survivors ◽

Differential Expression ◽

Candidate Genes ◽

Nerve Injury ◽

Breast Cancer Survivors ◽

Differential Methylation ◽

Sciatic Nerve Injury

Background Paclitaxel is an important chemotherapeutic agent for the treatment of breast cancer. Paclitaxel-induced peripheral neuropathy (PIPN) is a major dose-limiting toxicity that can persist into survivorship. While not all survivors develop PIPN, for those who do, it has a substantial negative impact on their functional status and quality of life. No interventions are available to treat PIPN. In our previous studies, we identified that the HIF-1 signaling pathway (H1SP) was perturbed between breast cancer survivors with and without PIPN. Preclinical studies suggest that the H1SP is involved in the development of bortezomib-induced and diabetic peripheral neuropathy, and sciatic nerve injury. The purpose of this study was to identify H1SP genes that have both differential methylation and differential gene expression between breast cancer survivors with and without PIPN. Methods A multi-staged integrated analysis was performed. In peripheral blood, methylation was assayed using microarray and gene expression was assayed using RNA-seq. Candidate genes in the H1SP having both differentially methylation and differential expression were identified between survivors who received paclitaxel and did (n = 25) and did not (n = 25) develop PIPN. Then, candidate genes were evaluated for differential methylation and differential expression in public data sets of preclinical models of PIPN and sciatic nerve injury. Results Eight candidate genes were identified as both differential methylation and differential expression in survivors. Of the eight homologs identified, one was found to be differential expression in both PIPN and “normal” mice dorsal root ganglia; three were differential methylation in sciatic nerve injury versus sham rats in both pre-frontal cortex and T-cells; and two were differential methylation in sciatic nerve injury versus sham rats in the pre-frontal cortex. Conclusions This study is the first to evaluate for methylation in cancer survivors with chronic PIPN. The findings provide evidence that the expression of H1SP genes associated with chronic PIPN in cancer survivors may be regulated by epigenetic mechanisms and suggests genes for validation as potential therapeutic targets.

Download Full-text